Company intelligence / Profile preview

CiberMed

Palo Alto, California, USAus-ciberweb.org ↗

Ownership: Private
Development stage: Other

Overview

CiberMed has commercialized iSort™, an AI-driven digital cytometry platform that enables high-resolution cellular profiling from bulk tissue or blood samples. The technology accelerates biomarker discovery and companion diagnostics development by providing robust cell type deconvolution at scale. It is trusted by leading pharmaceutical companies, diagnostic firms, academic researchers, and medical centers. The underlying algorithms are based on widely validated methods such as CIBERSORT/x developed at Stanford University.

Therapeutic areas: Women's HealthImmunologyOncologyOther
Modalities: Digital Cytometry (AI-powered computational tool)
Industry: Drug Discovery Services

Partnerships

Agilent Technologies

Beyond the preview

Go deeper on CiberMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CiberMed.

Explore the full profile